Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
10 Nov 2026, 07:31 PM

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

G
Guard News
@guardnews
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatmentThe gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by companies on weight loss, according to a report from the Netherlands-based non-profit group. Continue reading...
Source Credit: theguardian.com
Read Full Story
3

Comments (0)

Login to join the conversation
More News
More News
'Like gods reigning over humans': Many defectors see daughter of North Korea's Kim as heir apparent
10 Nov 2026
UK and Argentina clash over Falklands oil project as Hamburg tribunal starts
10 Nov 2026
Jordon Hudson files lawsuit over shirtless video of Belichick that helped disclose romance
10 Nov 2026
Historic ocean liner to ‘live on’ beneath waves as world’s biggest artificial reef
10 Nov 2026
Victorian Labor’s ‘unforgivable’ preferences decision risks Liberal-One Nation government, Greens warn
10 Nov 2026
Arrests made in Mohamed Al Fayed probe in France, police say
10 Nov 2026